Mayne Pharma enters Scheme Implementation Deed with Cosette
Filed with ASX · · 120 pages · English
Summary by 6ix AI
Mayne Pharma Group Ltd. has entered into a Scheme Implementation Deed with Cosette Pharmaceuticals, Inc. for the acquisition of Mayne Pharma at a specified cash price per share, which represents a significant premium to its recent share price. The Mayne Pharma Board unanimously recommends that shareholders vote in favor of the Scheme, pending an independent expert's conclusion that it is in their best interests. The transaction is fully funded and subject to customary conditions, including regulatory approvals and shareholder consent.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Watch Mayne Pharma's latest callMayne Pharma Group (ASX:MYX) Q4 2026 Earnings Call · Replay · Aug 26
Mayne Pharma Group Ltd. on 6ix
Earlier from Mayne Pharma
- Mayne Pharma market update
- 2024 AGM presentation and business update
- Mayne Pharma reports FY24 financial results
- 2024 Full Year Results Investor Presentation
- 2024 Full Year Results Media Release
Later from Mayne Pharma
- 2025 Half Year Media Release
- 2025 Half Year Investor Presentation
- Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S.
- Response to ASX Query
- Pause in Trade
Follow Mayne Pharma into a list and get an email when it puts out news.
Follow Mayne Pharma